KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $6.4 million.

  • Xenon Pharmaceuticals' Non-cash Items rose 709.92% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 709.92%. This contributed to the annual value of $5.9 million for FY2024, which is 9703.8% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Non-cash Items stood at $6.4 million, which was up 709.92% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Non-cash Items ranged from a high of $200.1 million in Q4 2023 and a low of $2.8 million during Q1 2021
  • Moreover, its 5-year median value for Non-cash Items was $5.4 million (2024), whereas its average is $27.7 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Non-cash Items soared by 24599.86% in 2021, and later crashed by 9703.8% in 2024.
  • Xenon Pharmaceuticals' Non-cash Items (Quarter) stood at $105.4 million in 2021, then soared by 39.67% to $147.2 million in 2022, then soared by 35.94% to $200.1 million in 2023, then tumbled by 97.04% to $5.9 million in 2024, then rose by 7.96% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $6.3 million for Q2 2025, and $6.5 million during Q1 2025.